Companies › Ascendis Pharma
3 active drug programs in 4 registered trials: 2 Phase 2, 2 Phase 3; Metabolic and endocrine, Other; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Palopegteriparatide Parathyroid hormone receptor agonist | PTH1R | Phase 3 | Hypoparathyroidism | Aug 2027 |
| Lonapegsomatropin Growth hormone receptor agonist | GHR | Phase 3 | Turner Syndrome | Feb 2028 |
| Navepegritide (TransCon CNP) | – | Phase 2 | Achondroplasia | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07706764 | Palopegteriparatide | Phase 3 | Hypoparathyroidism | Metabolic and endocrine | Aug 2027 |
| NCT06732895 | Navepegritide (TransCon CNP) | Phase 2 | Achondroplasia | Other | Sep 2027 |
| NCT06079398 | Navepegritide (TransCon CNP) | Phase 2 | Achondroplasia | Other | Dec 2027 |
| NCT07221851 | Lonapegsomatropin | Phase 3 | Turner Syndrome | Metabolic and endocrine | Feb 2028 |
Cash of 616m EUR on 2025-12-31; operating cash flow positive
Held by 12 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Ascendis Pharma Bone Diseases BioXTek HealthTech Wound Care PolarityTE Royal Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.